RAC NARROWLY APPROVES LIVER TUMOR GENE THERAPY PROTOCOL: DECISION SETS BAD "PRECEDENT" NORD EXEC DIRECTOR SAYS; IN UTERO ETHICS SUBCMTE. ESTABLISHED
Executive Summary
A gene therapy protocol treating liver cancer was narrowly approved by the National Institutes of Health Recombinant DNA Advisory Committee at a Dec. 2 meeting in Bethesda, Md. The committee approved the study by a margin of 10-7 after rejecting a motion to defer the trial by a vote of 8-9.